Preventing Arthritis in a Multi-Center Psoriasis At-Risk Cohort (Multi-Center PAMPA Study)

Brief description of study

Patients with psoriasis (PsO) are at a higher risk of developing psoriatic arthritis (PsA). About 1 in 3 patients with PsO will develop arthritis of the joints or spine, and specifically those added risk factors, including family history of PsA, nail psoriasis, scalp psoriasis and overweight. The purpose of this study is to evaluate the study drug TREMFYA (guselkumab) in high-risk psoriasis patients to study whether it can prevent progression of psoriasis to psoriatic arthritis when compared to placebo and to other standard of care treatment.

Clinical Study Identifier: s20-01158 Identifier: NCT05004727
Principal Investigator: Jose U Scher.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.